SUNI JACOB: Open Payments
NPI 1194709402 · HAMDEN, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,524 in 161 payments from 20 companies in 2025. Trend: 2023 $2,796 · 2024 $3,296 · 2025 $3,524
Food & beverage: $3,524
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 46 | $1,149 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 19 | $321 |
| Lilly USA, LLC | 16 | $298 |
| GlaxoSmithKline, LLC. | 15 | $297 |
| Novo Nordisk Inc | 10 | $260 |
| Esperion Therapeutics, Inc. | 7 | $193 |
| Novartis Pharmaceuticals Corporation | 11 | $190 |
| Amgen Inc. | 9 | $169 |
| Astellas Pharma US Inc | 4 | $112 |
| Phathom Pharmaceuticals, Inc. | 4 | $107 |
Products named: BREZTRI, JARDIANCE, FARXIGA, TRELEGY ELLIPTA, NEXLETOL, LEQVIO, OTEZLA, Veozah.
Industry payments across CT — which companies pay providers there.
